🇺🇸 Albuterol-HFA-MDI in United States
11 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 11
Most-reported reactions
- Alanine Aminotransferase Increased — 2 reports (18.18%)
- Aspartate Aminotransferase Increased — 1 report (9.09%)
- Blood Sodium Increased — 1 report (9.09%)
- Blood Urea Increased — 1 report (9.09%)
- Confusional State — 1 report (9.09%)
- Dehydration — 1 report (9.09%)
- Hypotension — 1 report (9.09%)
- Renal Failure Chronic — 1 report (9.09%)
- Rhabdomyolysis — 1 report (9.09%)
- Sepsis — 1 report (9.09%)
Other Respiratory approved in United States
Frequently asked questions
Is Albuterol-HFA-MDI approved in United States?
Albuterol-HFA-MDI does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Albuterol-HFA-MDI in United States?
Teva Branded Pharmaceutical Products R&D, Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.